NCT07642453Not yet recruitingPhase 2
VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.
VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
Objective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML). Key Research Questions: 1. Is the efficacy of the two-week VA-CAG regimen equivalent to that of the three-week regimen in inducing remission in AML? 2. Does the two-week VA-CAG regimen reduce treatment-related adverse events compared to the three-week regimen? Methods: Researchers will compare the efficacy and safety of the two-week VA-CAG regimen with the three-week regimen for induction remission in AML. Study participants will be randomly assigned to receive standard treatment with either the two-week or three-week VA-CAG regimen. Patients are required to attend monthly follow-up visits for a total of one year. At each follow-up, the following assessments will be performed: complete blood count, liver and kidney function tests, bone marrow aspiration, flow cytometric measurement of minimal residual disease (MRD), and/or fusion gene analysis, along with monitoring of other efficacy endpoints and adverse reactions.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 31 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Jun 2028
- Lead sponsor
- Hematology department of the 920th hospital
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07642453
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 110
- From 1 Jun 2026 to the primary completion date, 1 Jun 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior treatment;
Other illness
- Patients with other types of diseases;
- Severe psychiatric or neurological disorders that impair the ability to provide informed consent and/or report or observe adverse events;
Other
- Patients with a projected survival of less than 1 month;
- Other circumstances deemed unsuitable for enrollment by the investigator.
Who the study is looking for
- Diagnosis of acute myeloid leukemia confirmed according to NCCN guidelines;
- Age 18-75 years;
- Body weight 30-100 kg;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3;
- No significant organ dysfunction (echocardiographic ejection fraction \>45%; bilirubin \<2 times the upper limit of normal; AST and ALT \<3 times the upper limit of normal; serum creatinine \<2 times the upper limit of normal);
- No severe infections;
- Study participants voluntarily agree to participate in this clinical trial and sign an informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.